Subjects with preexisting cardiovascular symptoms who were receiving sibutramine, an appetite suppressant, were found to be at increased risk of cardiovascular events while taking the drug. The study included 98049804 overweight or obese subjects with preexisting cardiovascular disease and/or type 22 diabetes. The subjects were randomly assigned to sibutramine (49064906 subjects) or a placebo (48984898 subjects) in a doubleblind fashion. The primary outcome measured was the occurrence of any of the following events: nonfatal myocardial infarction or stroke, resuscitation after cardiac arrest, or cardiovascular death. The primary outcome was observed in 561561 subjects in the sibutramine group and 490490 subjects in the placebogroup.

W. P. T. James et al., "Effect of Sibutramine on cardiovascular outcomes in overweight and obese subjects," New England Journal of Medicine, 363 (2010), pp.905-917.

Macmillan Learning

Find the proportion of subjects experiencing the primary outcome for both the sibutramine and placebo groups. Give your answers to four decimalplaces.

sibutramine=^sibutramine=

placebo=^placebo=